SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer

Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer


  • Org Study ID: HS#2014-1758
  • Secondary ID:
  • NCT ID: NCT02957370
  • NCT Alias:
  • Sponsor: University of California, Irvine - Other
  • Source: University of California, Irvine

Brief Summary

This project focuses on developing specific and sensitive detectors of biomarker-based signatures associated with diagnosed and recurrent bladder cancer.

Detailed Description


The focus of this research is to discover urinary biomarker(s) that is distinct to bladder
cancer, while developing molecular sensors that can detect the urinary anomalies. By applying
in vitro selection techniques, both entities (biomarker discovery and sensor development)
will be done simultaneously.

All patients with bladder cancer diagnosis undergoing transurethral resection bladder tumor
(TURBT), those under surveillance for bladder cancer and patients presenting with microscopic
and visible (gross) hematuria will be invited to participate in the study. Patients will
undergo a standard of care evaluation as previously described (upper urinary tract imaging,
cystouretheroscopy and urine testing with urinalysis, culture and cytology).

Urine samples (10 mL) for the study will be collected prior to initial cystoscopy and/or
TURBT. The specimen will be barcoded and tracked by the UC Irvine Health software. Barcode
encoding will ensure that the identity of the patient and his/her clinical outcome will not
be available to the researchers for a blinded trial.

Patients involved in this study will only provide his or her urine for fundamental science
research; beyond that, standard of care will be provided for the patients. With respect to
the collected urine, it will be used as a medium for phage and aptamer production in an in
vitro fashion. The generated molecular probes will be use to assess and elucidate biomarkers
present for individuals with bladder cancer.

100 patients who are being monitored for bladder cancer will be the experimental group to
test the electro-phage and aptamer approach to following bladder cancer biomarkers.
Additionally, 100 patients being treated for hematuria will provide a negative control to
provide data from testing for biomarkers in patients being treated for other diseases.

Overal Status Start Date Phase Study Type
Recruiting Start Date: June 2015 Observational

Primary Outcomes:

Primary Outcome 1 - Measure: Urinary "Fingerprint" for Urinary Bladder Neoplasms

Primary Outcome 1 - Time Frame: Four Years

Condition:

  • Urinary Bladder Neoplasms

Eligibility

Criteria:
Inclusion Criteria:

- Patients ≥18 years old

- Patients with diagnosed bladder cancer, undergoing transurethral resection bladder
tumor (TRUBT), or under surveillance (within 2 years) for recurrent bladder cancer

- Patients with microscopic and macroscopic hematuria

- Willing and able to consent

Exclusion Criteria:

- Patients <18 years old

- Patients who are not able to give consent for study

- Patients with urinary diversions

- Patients who have had a recent percutaneous or endoscopic procedures for upper tract
diseases such as stones or other conditions

- Patients who have ureteral stents placed for upper urinary tract obstruction

- Patients with recent trauma in kidney, bladder or perineal area, which may be the
cause of hematuria

- Minors will be excluded from this study because ureteral stent placement is usually
performed in adult patients. Additionally, minors are treated at CHOC Hospital, and
not UCIMC.

- Women who are pregnant are excluded from this study since surgical treatments are not
typically performed on pregnant women. Watchful waiting is the preferred approach for
pregnant women. Furthermore, this research does not directly benefit the pregnant
woman or fetus, and biomedical knowledge can be obtained using subjects who are not
pregnant. Therefore, per the federal regulations, pregnant women will be excluded from
this study.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Jaime Landman, MD

Role: Principal Investigator

Affiliation: UC Irvine

Overall Contact

Name: Victor B Huynh, BS

Phone: 714-456-8176

Email: vbhuynh@uci.edu

Location

Facility Status Contact
University of California Irvine
Orange, California 92840
United States
Recruiting Victor Huynh, BS
714-456-8176
vbhuynh@uci.edu